What Hedge Funds Think of Valeant as It Tries to Increase Shareholder Value?

In two separate articles published this weekend, the New York Times noted how Valeant Pharmaceuticals Intl Inc (NYSE:VRX) management has cut R&D, raised drug prices, and avoided...

Keep Reading →